BOSTON, Sept. 4, 2014
/PRNewswire/ -- PAREXEL International Corporation (NASDAQ:
PRXL), a leading global biopharmaceutical services provider, today
announced the appointment of Dr. Tracy
Tsuetaki as Senior Vice President for Peri/Post-Approval
Services and PAREXEL Consulting. He will oversee the strategy
and operational management for both businesses. He will also
serve on PAREXEL's Business Review Committee, the Company's
senior-most leadership team, and assist in developing and
implementing PAREXEL's strategic objectives.
"In a competitive, global environment, customers are
increasingly seeking to accelerate drug development and build
market presence," said Mark A.
Goldberg, President and Chief Operating Officer,
PAREXEL. "Dr. Tsuetaki brings deep and wide-ranging industry
experience that will strengthen our ability to deliver innovative
peri- and post-approval services and consulting to the
industry."
Dr. Tsuetaki joins PAREXEL from UnitedHealth Group, where he
served as Group President for Optum Life Sciences. In that role, he
managed the Strategic Regulatory and Safety Services
organization. This encompassed pharmacovigilance, medical
information, pharmacoepidemiology, risk evaluation, and risk
mitigation strategies. It also included regulatory
affairs consulting and operations outsourcing, Chemical
Manufacturing and Control (CMC), Good Clinical Practice (GCP), and
Good Manufacturing Practice (GMP) services. Prior to this role, he
was Group President of i3, Inc. - Clinical Development
Services, also at United Healthcare Group. He led Phase I-III
clinical research and strategic regulatory offerings, as well as
resourcing and staffing services. His expertise also includes
international leadership of medical communications, post-marketing
and reimbursement business lines.
"PAREXEL is recognized for its global expertise across the
clinical-development spectrum, including late phase services and
consulting," said Dr. Tsuetaki. "In particular, the Company
has demonstrated leadership through its new regulatory outsourcing
services. I look forward to further building these offerings
to help customers address their post-marketing and regulatory
requirements."
Dr. Tsuetaki holds a B.S. in nutritional science from the
University of California at Davis, a
doctorate in optometry and a M.S. in physiological optics from the
University of California at Berkeley,
and an MBA from Northwestern
University's Kellogg Graduate School of Management.
About PAREXEL International
PAREXEL International
Corporation is a leading global biopharmaceutical services
organization, providing a broad range of knowledge-based contract
research, consulting, medical communications, and technology
solutions and services to the worldwide pharmaceutical,
biotechnology and medical device industries. Committed to providing
solutions that expedite time-to-market and peak-market penetration,
PAREXEL has developed significant expertise across the development
and commercialization continuum, from drug development and
regulatory consulting to clinical pharmacology, clinical trials
management, medical education and reimbursement. PAREXEL
Informatics, Inc. provides advanced technology solutions, including
medical imaging, to facilitate the clinical development process.
Headquartered near Boston,
Massachusetts, PAREXEL operates in 80 locations in 51
countries around the world, and has approximately 15,560
employees. For more information about PAREXEL International
visit www.PAREXEL.com.
PAREXEL and "Your Journey. Our Mission." are trademarks or
registered trademarks of PAREXEL International Corporation or its
affiliates.
This release contains "forward-looking" statements regarding
future results and events. For this purpose, any
statements contained herein that are not statements of historical
fact may be deemed forward-looking statements. Without
limiting the foregoing, the words "believes," "anticipates,"
"plans," "expects," "intends," "appears," "estimates," "projects,"
"will," "would," "could," "should," "targets," and similar
expressions are also intended to identify forward-looking
statements. The forward-looking statements in this release
involve a number of risks and uncertainties. The Company's
actual future results may differ significantly from the results
discussed in the forward-looking statements contained in this
release. Important factors that might cause such a difference
include, but are not limited to, risks associated with: actual
operating performance; actual expense savings and other operating
improvements resulting from recent and anticipated restructurings;
the loss, modification, or delay of contracts which would, among
other things, adversely impact the Company's recognition of revenue
included in backlog; the Company's dependence on certain industries
and clients; the Company's ability to win new business, manage
growth and costs, and attract and retain employees; the Company's
ability to complete additional acquisitions, and to integrate newly
acquired businesses including the recent acquisitions of LIQUENT,
Inc. and HERON, Inc., or enter into new lines of business; the
impact on the Company's business of government regulation of the
drug, medical device and biotechnology industry;
consolidation within the pharmaceutical industry and competition
within the biopharmaceutical services industry; the potential for
significant liability to clients and third parties; the potential
adverse impact of health care reform; and the effects of exchange
rate fluctuations and other international economic, political, and
other risks. Such factors and others are discussed more
fully in the section entitled "Risk Factors" of the Company's
Annual Report on Form 10-K for the fiscal year ended June 30, 2014 as filed with the SEC on
August 20, 2014, which "Risk Factors"
discussion is incorporated by reference in this press
release. The Company specifically disclaims any obligation to
update these forward-looking statements in the future. These
forward-looking statements should not be relied upon as
representing the Company's estimates or views as of any date
subsequent to the date of this press release.
Contacts:
Diana Martin, Vice President,
Corporate Communications
PAREXEL International
Tel: +1 781-434-5516
Email: Diana.Martin@PAREXEL.com
Matthew Briggs
PAN Communications
Tel: +1 617-502-4300
Email: PAREXEL@pancomm.com
SOURCE PAREXEL International Corporation